The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is meeting this week to consider whether seven widely discussed peptides should be eligible for compounding by 503A pharmacies. This is a decision that could significantly impact compounding pharmacies, healthcare providers, telehealth companies, and the broader peptide industry. An article in CNN Health examines the growing popularity of peptides, the expanding gray market, and the ongoing debate between advocates who argue that regulated compounding could improve patient safety and critics who caution that many of the peptides lack sufficient clinical evidence supporting their safety and effectiveness.
In the article, Edgar Asebey emphasized that none of the peptides under review are FDA-approved drugs and that significant questions remain regarding their long-term safety, efficacy, and potential adverse effects. Jesse Dresser highlighted the significant business implications of the FDA’s review, noting that compounding pharmacies, telehealth companies, and investors are already positioning themselves for potential regulatory changes that could reshape the peptide marketplace. Together, their insights underscore both the regulatory complexities and the commercial opportunities surrounding one of the most closely watched FDA proceedings of the year.
To learn more about the FDA’s review of these seven peptides and what the PCAC meeting could mean for compounding pharmacies, telehealth companies, healthcare providers, and the broader peptide industry, watch Frier Levitt’s on-demand webinar featuring Edgar Asebey and Jesse Dresser.
